A follow-up to "anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg

Arthritis Research

Volumn 3, Issue 4, 2001, Pages 211-213

  Brennan, F M ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Anti TNF; IL 1; IL 1 ra; Rheumatoid arthritis; TNF

Indexed keywords

CYTOKINE; CYTOKINE ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC ARTHRITIS; DRUG EFFICACY; DRUG TARGETING; FOLLOW UP; HYPOTHESIS; INFLAMMATION; MOUSE; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; TISSUE INJURY;

ANIMALS; ANTIBODIES; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-1; MICE; MICE, TRANSGENIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034935779     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar302     Document Type: Article

References (26)

1. Anti-cytokine therapy in chronic destructive arthritis
2. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
3. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: Characterization of the cytokine cascade and cellular composition
4. Translational blockade imposed by cytokine-derived UA-rich sequences
5. Constitutive activity of the tumor necrosis factor promoter is canceled by the 3′ untranslated region in nonmacrophage cell lines; a trans-dominant factor overcomes this suppressive effect
6. The type 1 interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice
7. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy
8. The interleukin-1 family: 10 years of discovery
9. A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis
10. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis
11. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis
12. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis
13. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis
14. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis
15. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti- tumour necrosis factor-alpha (cA2) therapy
16. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis
17. Cytokine appearance in human endotoxemia and primate bacteremia
18. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia
19. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
20. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis
21. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: Comparison of monoclonal anti-TNFα antibody with the IL-1 receptor antagonist
22. Interleukin-1 receptor antagonist: Role in biology
23. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
24. Gene therapy for arthritis: Principles and clinical practice
25. Infliximab and methotrexate in the treatment of rheumatoid arthritis
26. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis